Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Addex Therapeutics Ltd ADR (ADXN)

Addex Therapeutics Ltd ADR (ADXN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 38,076
  • Shares Outstanding, K 10,879
  • Annual Sales, $ 3,190 K
  • Annual Income, $ -16,800 K
  • 60-Month Beta 1.57
  • Price/Sales 11.73
  • Price/Cash Flow N/A
  • Price/Book 2.97
Trade ADXN with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.52
  • Number of Estimates 1
  • High Estimate -0.52
  • Low Estimate -0.52
  • Prior Year -0.77
  • Growth Rate Est. (year over year) +32.47%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.19 +9.72%
on 05/17/22
5.40 -35.19%
on 04/26/22
-1.42 (-28.86%)
since 04/22/22
3-Month
3.19 +9.72%
on 05/17/22
6.24 -43.91%
on 02/25/22
-2.06 (-37.05%)
since 02/23/22
52-Week
3.19 +9.72%
on 05/17/22
11.48 -69.51%
on 06/11/21
-6.50 (-65.00%)
since 05/21/21

Most Recent Stories

More News
Addex Shareholders Approve All Resolutions at Annual General Meeting

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 10, 2022 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company...

ADXN : 3.50 (-5.91%)
Addex Therapeutics Ltd. Sponsored ADR (ADXN) Reports Q1 Loss, Misses Revenue Estimates

Addex Therapeutics Ltd. Sponsored ADR (ADXN) delivered earnings and revenue surprises of -86.54% and 49.61%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead...

ADXN : 3.50 (-5.91%)
PRPH : 8.47 (+10.14%)
Addex Reports Q1 2022 Financial Results

CHF14.9M ($16.1M) of cash and cash equivalents at March 31, 2022Dipraglurant Phase 2 blepharospasm clinical trial on track to report data in Q2 2022Phase...

ADXN : 3.50 (-5.91%)
Addex Convenes Annual General Meeting 2022

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, March 31, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage...

ADXN : 3.50 (-5.91%)
Addex Therapeutics Ltd. Sponsored ADR (ADXN) Upgraded to Buy: What Does It Mean for the Stock?

Addex Therapeutics Ltd. Sponsored ADR (ADXN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

ADXN : 3.50 (-5.91%)
Addex to Present at the Bio-Europe Spring 2022 and Maxim Group – 2022 Virtual Growth Conferences

Geneva, Switzerland, March 24, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...

ADXN : 3.50 (-5.91%)
Addex Therapeutics Ltd. Sponsored ADR (ADXN) Reports Q4 Loss, Lags Revenue Estimates

Addex Therapeutics Ltd. Sponsored ADR (ADXN) delivered earnings and revenue surprises of -25.76% and 16.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead...

ADXN : 3.50 (-5.91%)
RVLP : 1.3700 (-0.72%)
Addex Reports Full Year 2021 Financial Results and Provides Corporate Update

CHF20.5M ($22.5M) of cash and cash equivalents at December 31, 2021Dipraglurant Phase 2 blepharospasm clinical trial on track to report data in Q2...

ADXN : 3.50 (-5.91%)
Addex to Present at the Virtual Sachs Associates 3rd Annual European HealthTech and 15th Annual European Life Sciences CEO Forums

Geneva, Switzerland, February 24, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...

ADXN : 3.50 (-5.91%)
Addex Therapeutics Ltd. Sponsored ADR (ADXN) Moves to Buy: Rationale Behind the Upgrade

Addex Therapeutics Ltd. Sponsored ADR (ADXN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

ADXN : 3.50 (-5.91%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Addex Therapeutics Ltd is a clinical-stage pharmaceutical company. It is focused on the development and commercialization of small molecule drugs for neurological disorders. The company's lead drug candidate includes dipraglurant, ADX71149 which are in clinical stage. Its Preclinical programs include...

See More

Key Turning Points

3rd Resistance Point 4.18
2nd Resistance Point 4.05
1st Resistance Point 3.77
Last Price 3.50
1st Support Level 3.36
2nd Support Level 3.23
3rd Support Level 2.95

See More

52-Week High 11.48
Fibonacci 61.8% 8.31
Fibonacci 50% 7.34
Fibonacci 38.2% 6.36
Last Price 3.50
52-Week Low 3.19

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar